Delayed growth of Ewing sarcoma tumors associated with reduced expression and activity of Trk receptors, PI3K, and IGF1R
dos Santos, B. A.; Freire, N. H.; Fratini, L.; Dalmolin, M.; de Castro, J. M.; Fernandes, M. A. C.; Gregianin, L.; Brunetto, A. T.; Brunetto, A. L.; Rivero, L. F. d. R.; Jaeger, M. d. C.; Roesler, R.; de Farias, C. B.
Show abstract
Ewing sarcoma (ES) is an aggressive childhood tumor. We have previously shown that tropomyosin receptor kinase (Trk) neurotrophin receptors regulate viability, and the pan-Trk and kinase inhibitor K252a restores sensitivity to chemotherapy, in ES cells. Here, we show that administration of K252a in mice delays ES tumor growth and reduces expression and activity of multiple targets. BALB/c nu/nu nude mice inoculated with SK-ES-1 ES cells were given daily intraperitoneal (i.p.) injections of K252a for 18 days. Immunohistochemical analysis of tumors was performed to quantify the expression and phosphorylation of Trk receptors, phosphoinositide 3-kinase (PI3K), and insulin-like growth factor 1 receptor (IGF1R). Associations between genes encoding Trks, PI3G, and IGF1R and overall survival (OS) in patients with ES was examined. Treatment with K252a led to a transient delay in ES tumor growth and reduced the expression and phosphorylation of TrkA, TrkB, PI3K, and IGF1R. Combined treatment with K252a and the IGF1R inhibitor NVP-ADW742 was more effective in reducing ES cell viability than each compound alone. Significant associations between expression of NTRK genes and patient OS were found, indicating that NTRK genes should be further evaluated as biomarkers for prognosis in patients with ES.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 95%
- Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor 94%
- Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting 93%
Similar papers in this journal
- Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor 95%
- Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models 94%
- Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the Bladder 94%
Similar papers in this journal
- Targeting the translational machinery in gastrointestinal stromal tumors (GIST) - a new therapeutic vulnerability 95%
- Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer 94%
- Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages 93%
Similar papers in this journal
- Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers 95%
- Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors 93%
- An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer 93%
Similar papers in this journal
- Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS) 94%
- Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase 93%
- High-dose DFMO alters protein translation in neuroblastoma 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.